{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:43:17Z","timestamp":1790862197731,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":116,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008605.pub2","type":"reference-entry","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T20:02:33Z","timestamp":1328904153000},"source":"Crossref","is-referenced-by-count":39,"title":["Cabergoline for preventing ovarian hyperstimulation syndrome"],"prefix":"10.1002","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"10.1002\/14651858.CD008605.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"Alvarez","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD008605.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reproductive Biomedicine Online"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1472-6483(10)60043-0","article-title":"Symposium: Update on prediction and management of OHSS - Prevention of OHSS","volume":"19","author":"Aboulghar","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1055\/s-0030-1265681","article-title":"Treatment of ovarian hyperstimulation syndrome","volume":"28","author":"Aboulghar","year":"2010","journal-title":"Seminars in Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1472-6483(10)62518-7","article-title":"Cabergoline versus human albumin in prophylaxy of ovarian hyperstimulation syndrome","volume":"20","author":"Ahmadi","year":"2010","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0020-7292(09)60407-0","article-title":"Spontaneous ovarian hyperstimulation syndrome (OHSS)","volume":"107","author":"Al-Mandhari","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD008605.pub2-BIB7|cit7","first-page":"i96","article-title":"The dopamine agonist Cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients","volume":"21 Suppl","author":"Alvarez","year":"2006","journal-title":"Human Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.fertnstert.2009.05.021","article-title":"High dose cabergoline in management of ovarian hyperstimulation syndrome","volume":"92","author":"Ata","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/eog.09.10","article-title":"Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment","volume":"4","author":"Ata","year":"2009","journal-title":"Expert Review of Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB10|cit10","first-page":"19","article-title":"Ovarian hyperstimulation syndrome. [Spanish]","volume":"32 Suppl 1","author":"Azcona Ruiz","year":"2009","journal-title":"Anales del Sistema Sanitario de Navarra"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB11|cit11","first-page":"4","article-title":"Controlled ovarian stimulation in difficult cases","volume":"9","author":"Badawy","year":"2011","journal-title":"Sexuality, Reproduction and Menopause"},{"key":"10.1002\/14651858.CD008605.pub2-BIB12|cit12","first-page":"CD002249","article-title":"Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation","volume":"1","author":"Beck","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008605.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/S0020-7292(09)62278-5","article-title":"Our clinical experiences with use of cabergoline in treatment of OHSS","volume":"107","author":"Bjelica","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccm.2008.10.004","article-title":"Obstetric disorders in the ICU","volume":"30","author":"Bourjeily","year":"2009","journal-title":"Clinics in Chest Medicine"},{"key":"10.1002\/14651858.CD008605.pub2-BIB15|cit15","first-page":"CD002249","article-title":"Clomiphene and anti-oestrogens for ovulation induction in PCOS","volume":"4","author":"Brown","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1472-6483(10)60044-2","article-title":"Symposium: Update on prediction and management of OHSS: Prevention of OHSS - Dopamine agonists","volume":"19","author":"Busso","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.mefs.2010.06.013","article-title":"Prevention of OHSS: Current strategies and new insights","volume":"15","author":"Busso","year":"2010","journal-title":"Middle East Fertility Society Journal"},{"key":"10.1002\/14651858.CD008605.pub2-BIB19|cit19","series-title":"Human Reproduction","first-page":"i141","article-title":"Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg\/ml on the day of the hCG","author":"Carizza","year":"2008"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1472-6483(10)60065-X","article-title":"Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma","volume":"19","author":"Castelo-Branco","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/0008-5472.CAN-08-4289","article-title":"Catecholamines regulate tumor angiogenesis","volume":"69","author":"Chakroborty","year":"2009","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/humrep\/dep432","article-title":"Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: Dopamine targets their common pathways","volume":"25","author":"Chen","year":"2010","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tjog.2011.01.014","article-title":"Update on management of ovarian hyperstimulation syndrome","volume":"50","author":"Chen","year":"2011","journal-title":"Taiwanese Journal of Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1028-4559(09)60003-6","article-title":"Differential diagnosis of gynecologic organ-related diseases in women presenting with ascites","volume":"47","author":"Cheng","year":"2008","journal-title":"Taiwanese Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB25|cit25","first-page":"2","article-title":"The role of low dose cabergoline and gonodatropin releasing hormone antagonist in prevention of ovarian hyperstimulation syndrome (OHSS) - a case series","volume":"50","author":"Chua","year":"2010","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB26|cit26","first-page":"119","article-title":"In-vitro fertilisation. [Polish]","volume":"3","author":"Coughlan","year":"2009","journal-title":"Poloznictwo Ginekologia i Medycyna Rozrodu"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB27|cit27","first-page":"41","article-title":"Ovulation induction in poor responders: A review","volume":"14","author":"Albuquerque","year":"2010","journal-title":"Jornal Brasileiro de Reproducao Assistida"},{"key":"10.1002\/14651858.CD008605.pub2-BIB28|cit28","first-page":"93","article-title":"Bromocryptin + gonadotropin vs goserelin + gonadotropin in ovulation induction in patients with polycystic ovaries","volume":"47","author":"Vita","year":"1995","journal-title":"Minerva Ginecologica"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB29|cit29","first-page":"18","article-title":"Assisted reproductive technology (ART): Combating infertility","volume":"4","author":"Desai","year":"2011","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/humrep\/den468","article-title":"Improving the patient's experience of IVF\/ICSI: A proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment","volume":"24","author":"Devroey","year":"2009","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub2-BIB31|cit31","first-page":"i57","article-title":"Dopamine receptor 2 (drd2) activation inhibits VEGF secretion in granulosa luteinized cells: Implications for OHSS treatment in low drd2 milieus","volume":"25","author":"Ferrero","year":"2010","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub2-BIB32|cit32","first-page":"341A","article-title":"Drd2 agonists prevent prevents OHSS by reducing VEGF secretion through the activation of Drd2 in granulosa cells","volume":"18 Suppl 3","author":"Ferrero","year":"2011","journal-title":"Reproductive Sciences"},{"key":"10.1002\/14651858.CD008605.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1472-6483(10)60452-X","article-title":"How to avoid ovarian hyperstimulation syndrome: A new indication for dopamine agonists","volume":"18 Suppl 2","author":"Garcia-Velasco","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"15","key":"10.1002\/14651858.CD008605.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1517\/14656566.2010.499359","article-title":"Pharmacotherapy of ovarian hyperstimulation syndrome","volume":"11","author":"Genazzani","year":"2010","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0030-1265670","article-title":"Physiology and pathology of ovarian hyperstimulation syndrome","volume":"28","author":"Gomez","year":"2010","journal-title":"Seminars in Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub2-BIB36|cit36","first-page":"294A","article-title":"Differential expression of dopamine receptor 2 (DRD2) might account for higher risk of OHSS development","volume":"18(suppl 3)","author":"Gomez","journal-title":"Reproductive Sciences"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1210\/jc.2011-0075","article-title":"Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: Implications for OHSS development and treatment","volume":"96","author":"Gomez","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.fertnstert.2010.07.705","article-title":"The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS","volume":"94 Suppl","author":"Guvendag Guven","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB39|cit39","first-page":"256","article-title":"Quinagolide reduces OHSS in high risk ICSI patients","volume":"7","author":"Halabi","year":"2010","journal-title":"Journal fur Reproduktionsmedizin und Endokrinologie"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB40|cit40","first-page":"381","article-title":"Author's reply: Ovarian hyperstimulation syndrome","volume":"52","author":"Hemashree","year":"2011","journal-title":"Singapore Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1878-3317(10)60010-1","article-title":"Preventive strategies of ovarian hyperstimulation syndrome","volume":"2","author":"Huang","year":"2010","journal-title":"Journal of Experimental and Clinical Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub2-BIB43|cit43","first-page":"541","article-title":"Preventing ovarian hyperstimulation syndrome: Guidance for the clinician","volume":"27","author":"Humaidan","year":"2010","journal-title":"Revista Iberoamericana de Fertilidad y Reproduccion Humana"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijgo.2009.09.017","article-title":"Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels","volume":"108","author":"Hwang","year":"2010","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000181564","article-title":"A study on follicle stimulation and ovulation induction in polycystic ovary syndrome (PCOS)","volume":"33","author":"Ito","year":"1990","journal-title":"Hormone Research"},{"issue":"11","key":"10.1002\/14651858.CD008605.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/jcem.82.11.4349","article-title":"A therapeutic role of prolactin supplementation in ovarian stimulation for in vitro fertilization: the bromocriptine-rebound method","volume":"82","author":"Jinno","year":"1997","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0015-0282(16)59769-6","article-title":"Hypoprolactinemia and ovarian function","volume":"49","author":"Kauppila","year":"1988","journal-title":"Fertility and Sterility"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.fertnstert.2010.01.096","article-title":"Cabergoline and ganirelix therapy for early moderate to severe ovarian hyperstimulation syndrome (OHSS) results in faster recovery than in early untreated OHSS","volume":"93 Suppl 1","author":"Khan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB49|cit49","first-page":"305","article-title":"Use of cabergolin for prevention of ovarian hyperstimulation syndrome","volume":"7","author":"Krasnopolsckaya","year":"2010","journal-title":"Journal fur Reproduktionsmedizin und Endokrinologie"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/jp.2008.116","article-title":"High-risk pregnancy management in women with hypopituitarism","volume":"29","author":"Kubler","year":"2009","journal-title":"Journal of Perinatology"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0015-0282(16)60787-2","article-title":"Prolactin suppression by bromocriptine stimulates aromatization of testosterone to estradiol in women","volume":"52","author":"Martikainen","year":"1989","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.fertnstert.2009.03.081","article-title":"Adjuncts for ovarian stimulation: when do we adopt \"orphan indications\" for approved drugs?","volume":"92","author":"Meldrum","year":"2009","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S1472-6483(10)62626-0","article-title":"Adjuncts for COH - Metformin, growth hormone, androgens and more","volume":"20","author":"Meldrum","year":"2010","journal-title":"Reproductive Biomedicine Online"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/humrep\/dep434","article-title":"A fatal case of ovarian hyperstimulation syndrome with perforated duodenal ulcer","volume":"25","author":"Memarzadeh","year":"2010","journal-title":"Human Reproduction"},{"issue":"11-2","key":"10.1002\/14651858.CD008605.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.gyobfe.2009.06.007","article-title":"Ovarian stimulation and follicular puncture risks. [French]","volume":"37","author":"Merviel","year":"2009","journal-title":"Gynecologie Obstetrique Fertilite"},{"key":"10.1002\/14651858.CD008605.pub2-BIB56|cit56","first-page":"54","article-title":"Ovarian hyperstimulation syndrome in ART pregnancies possibilities for treatment","volume":"23","author":"Motrenko","year":"2010","journal-title":"Journal of Maternal-Fetal and Neonatal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB57|cit57","first-page":"211","article-title":"Infertility and pregnancy in women with polycystic ovary syndrome","volume":"35","author":"Nader","year":"2010","journal-title":"Minerva Endocrinologica"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB58|cit58","first-page":"132","article-title":"Clinical utility of cabergoline in ovarian hyperstimulation syndrome","volume":"58","author":"Nagore Setien","year":"2011","journal-title":"Revista Espanola de Anestesiologia y Reanimacion"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1472-6483(10)60039-9","article-title":"Symposium: Update on prediction and management of OHSS - Introduction","volume":"19","author":"Nardo","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"2-3","key":"10.1002\/14651858.CD008605.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10815-010-9387-6","article-title":"Ovarian hyperstimulation syndrome: Pathophysiology and prevention","volume":"27","author":"Nastri","year":"2010","journal-title":"Journal of Assisted Reproduction and Genetics"},{"key":"10.1002\/14651858.CD008605.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000181926","article-title":"Effects of prolactin on fertilization and cleavage of human oocytes","volume":"35","author":"Oda","year":"1991","journal-title":"Hormone Research"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB62|cit62","first-page":"137","article-title":"Ovulation induction in IVF","volume":"63","author":"Oehninger","year":"2011","journal-title":"Minerva Ginecologica"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/oxfordjournals.humrep.a136913","article-title":"Suppression of prolactin secretion during ovarian hyperstimulation is followed by elevated serum levels of endometrial protein pp14 in the late luteal phase","volume":"4","author":"Pala","year":"1989","journal-title":"Human Reproduction"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ogrm.2009.05.003","article-title":"Ovarian hyperstimulation syndrome: pathophysiology, prevention and management","volume":"19","author":"Prakash","year":"2009","journal-title":"Obstetrics, Gynaecology and Reproductive Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB65|cit65","first-page":"39","article-title":"Ovarian hyperstimulation syndrome: Pathophysiology, prevention and management. [Polish]","volume":"4","author":"Prakash","year":"2010","journal-title":"Poloznictwo Ginekologia i Medycyna Rozrodu"},{"issue":"12","key":"10.1002\/14651858.CD008605.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ogrm.2009.09.004","article-title":"Management of the critically ill obstetric patient","volume":"19","author":"Price","year":"2009","journal-title":"Obstetrics, Gynaecology and Reproductive Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB67|cit67","first-page":"160","article-title":"Historical background and review of drugs and methods used for induction of ovulation part II","volume":"20","author":"Rajab","year":"2008","journal-title":"Journal of the Bahrain Medical Society"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB68|cit68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0974-1208.69330","article-title":"Journal of Human Reproductive Sciences: From the editor's desk","volume":"3","author":"Rao","year":"2010","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1169.e15","DOI":"10.1016\/j.fertnstert.2009.05.062","article-title":"Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2009.07.1598","article-title":"Cabergoline and ganirelix treatment of ovarian hyperstimulation syndrome (OHSS) results in rapid clinical improvement","volume":"92 Suppl 3","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.fertnstert.2010.01.112","article-title":"Migraine history is a major risk factor for ovarian hyperstimulation syndrome","volume":"93 Suppl 1","author":"Rollene","year":"2010","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB72|cit72","first-page":"264A","article-title":"Migraines as a predictor for ovarian hyperstimulation syndrome: The dopamine connection","volume":"17 Suppl 3","author":"Rollene","year":"2010","journal-title":"Reproductive Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.fertnstert.2010.08.041","article-title":"Migraines and ovarian hyperstimulation syndrome: A dopamine connection","volume":"95","author":"Rollene","year":"2011","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1472-6483(10)62459-5","article-title":"Prevention of OHSS - An evidence-based approach","volume":"20","author":"Sallam","year":"2010","journal-title":"Reproductive Biomedicine Online"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.2011.05983.x","article-title":"Intensive care treatment of ovarian hyperstimulation syndrome (OHSS)","volume":"1221","author":"Sansone","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.rx.2008.03.001","article-title":"Magnetic resonance for evaluating the response to treatment for ovarian hyperstimulation syndrome: comparison of pharmokinetic models","volume":"51","author":"Sanz Requena","year":"2009","journal-title":"Radiologia"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/00016341003592537","article-title":"Prevention of ovarian hyperstimulation syndrome in a rat model: Efficacy comparison between cabergoline and meloxicam","volume":"89","author":"Saylan","year":"2010","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/oxfordjournals.humrep.a136913","article-title":"Suppression of prolactin secretion during ovarian hyperstimulation is followed by elevated serum levels of endometrial protein PP14 in the late luteal phase","volume":"4","author":"Seppala","year":"1989","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-1208.69342","article-title":"Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction","volume":"3","author":"Sherwal","year":"2010","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","article-title":"Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome","volume":"14","author":"Soares","year":"2008","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB81|cit81","first-page":"35","article-title":"Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients","volume":"3","author":"Sohrabvand","year":"2009","journal-title":"International Journal of Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mefs.2010.10.004","article-title":"Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome","volume":"16","author":"Soliman","year":"2011","journal-title":"Middle East Fertility Society Journal"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0015-0282(16)60976-7","article-title":"Bromocriptine inhibition of anesthesia-induced hyperprolactinaemia: effect on serum and follicular fluid hormones - oocyte fertilization and embryo cleavage rates during in vitro fertilzation","volume":"52","author":"Sopelak","year":"1989","journal-title":"Fertility and Sterility"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub2-BIB84|cit84","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.fertnstert.2011.02.032","article-title":"Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome","volume":"95","author":"Spitzer","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.fertnstert.2011.04.018","article-title":"Reply of the authors","volume":"95","author":"Spitzer","year":"2011","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB86|cit86","first-page":"S77","article-title":"Pregnancy following laparoscopic ovarian drilling in PCOD","volume":"7","author":"Valenti","year":"2010","journal-title":"Gynecological Surgery"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub2-BIB87|cit87","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/humrep\/deq062","article-title":"Human Reproduction: Editor's Choice","volume":"25","author":"Steirteghem","year":"2010","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub2-BIB88|cit88","first-page":"119","article-title":"Controlled ovarian hyperstimulation: A review for the non-ART patient","volume":"63","author":"Willis","year":"2011","journal-title":"Minerva Ginecologica"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB89|cit89","first-page":"381","article-title":"Ovarian hyperstimulation syndrome","volume":"52","author":"Wiwanitkit","year":"2011","journal-title":"Singapore Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.fertnstert.2011.04.017","article-title":"Prevention of ovarian hyperstimulation syndrome","volume":"95","author":"Wiwanitkit","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB91|cit91","first-page":"i60","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone","volume":"24","author":"Salah Edeen","year":"2009","journal-title":"Human Reproduction"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD008605.pub2-BIB93|cit93","first-page":"i61 O-154 Oral","article-title":"Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome","volume":"24 Suppl 1","author":"Shaltout","year":"2009","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub2-BIB94|cit94","unstructured":"Tehraninejad E Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program ClinicalTrials.gov Identifier:NCT01009567"},{"key":"10.1002\/14651858.CD008605.pub2-BIB95|cit95","unstructured":"Tehraninejad E The efficacy of cabergoline in preventing ovarian hyper stimulation in ART program Irct registration number : IRCT138808271141N7"},{"key":"10.1002\/14651858.CD008605.pub2-BIB96|cit96","first-page":"Art.No.: CD0013","article-title":"Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome","volume":"Issue 2","author":"Aboulghar","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD008605.pub2-BIB98|cit98","first-page":"No.: CD002811.","article-title":"Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome","volume":"Issue 3. Art","author":"D'Angelo","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008605.pub2-BIB99|cit99","first-page":"Art. No.: CD002","article-title":"Embryo freezing for preventing ovarian hyperstimulation syndrome","volume":"Issue 3","author":"D'Angelo","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/humupd\/8.3.291","article-title":"A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients","volume":"18","author":"Delvigne","year":"2002","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1472-6483(10)60699-2","article-title":"IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink","volume":"15","author":"Edwards","year":"2007","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstetrical & Gynecological Survey"},{"key":"10.1002\/14651858.CD008605.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"G\u00f3mez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB106|cit106","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"719 e15-8","DOI":"10.1016\/j.fertnstert.2006.01.055","article-title":"Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas","volume":"86","author":"Knoepfelmacher","year":"2006","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub2-BIB108|cit108","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB110|cit110","unstructured":"Cochrane Menstrual Disorders and Subfertility Group Module www.mrw.interscience.wiley.com\/cochrane\/cochrane_clsysrev_crglist_fs.html"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub2-BIB111|cit111","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-9378(67)90137-8","article-title":"Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment","volume":"98","author":"Rabau","year":"1967","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB112|cit112","first-page":"11p","article-title":"The management of ovarian hyperstimulation syndrome","volume":"Sept","year":"2006","journal-title":"London (UK): Royal College of Obstetricians and Gynaecologists (RCOG)"},{"key":"10.1002\/14651858.CD008605.pub2-BIB113|cit113","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub2-BIB114|cit114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub2-BIB115|cit115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2009.02.006","article-title":"Ovarian hyperstimulation syndrome and complications of ART","volume":"23","author":"Vloeberghs","year":"2009","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"key":"10.1002\/14651858.CD008605.pub2-BIB116|cit116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"New England Journal of Medicine"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008605.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008605.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:21:54Z","timestamp":1628547714000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008605.pub2"}},"subtitle":[],"editor":[{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":116,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008605.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008605.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,2,15]]}}}